🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We rarely have a moment to return to our roots; the place that made us; re-visit the spirit of the mentors who molded us. UTSW Heart UT Southwestern Medical Center - I am forever grateful 🙏🏽🙏🏽🙏🏽 Amit Khera Mark Drazner Gail Peterson Doug V NM Cardiovascular

< 2 wks to #ASCO25, here is a📝 of 🔑abstracts for general onc that could guide our SoC! - #ATOMIC - #MATTERHORN - #SERENA6 - #ASCENT04 - #DestinyBreast09 - #IMforte & #Dellphi304 - Updates: #CM816 & #NIAGARA - #NIVOPOSTOP - #VERIFY #OncTwitter ASCO OncoAlert

Truly remarkable!

DAPA-HF & EMPEROR-Reduced trials reveal significant absolute risk reductions in cardiovascular, renal, & mortality outcomes with dapagliflozin and empagliflozin. SGLT2 inhibitors continue to redefine heart failure and CKD management. tandfonline.com/doi/full/10.10…

🔥 Out in Nature Genetics our latest work on APOBEC3 in breast cancer 📌 Key takeaways - APOBEC3 activity is pervasive - even before treatment - It plays a central role in therapy resistance - APOBEC3 may serve as a predictive biomarker and therapeutic target See thread👇

#ATTR Early-Career Research #Forum winner Senthil Selvaraj, MD, MS, MA continuing impactful work in #amyloid!

Presented at #ATS2025: In the FIBRONEER-IPF phase 3 trial, nerandomilast slowed disease progression in patients with idiopathic pulmonary fibrosis as compared with placebo. Full trial results: nej.md/4mgWcIU American Thoracic Society (ATS)

⚠️⚠️⚠️ Great summary of red flags in clinical history, examination, and imaging that should prompt consideration of cardiac amyloidosis by Pablo Garcia-Pavia to close #HeartFailure2025 #MedIQHF2025

Excellent study linking acoramidis, TTR levels, & mortality in ATTRIBUTE-CM now in JACC Journals Congrats Jessica Regan on leading our accompanying editorial (bit.ly/436F0i0) & 🙏 outstanding collaborators Michelle Kittleson MD PhD Michel Khouri Frederick L Ruberg Duke Heart

3 out of 7 newly diagnosed ATTR-CM patients that I saw in 1 day didnt have ATTR-CM (2 on therapy). Just really tough to interpret PYP scans with blood pooling, and due to cavity size and shape they simply appeared as myocardial uptake to those reading them. That is why we are

In Case You Missed It: In last week's #ARCTALKS Webinar, Senior Research Manager, Sabrina Rebello, presented an in-depth overview of key insights from our Annual #Amyloidosis Community Survey: arci.org/resource/under…

HFpEF affects ~4M in the U.S. Once lacking therapies, HFpEF is now seeing rapid progress—with SGLT2i, Ns-MRAs, and GLP-1 RAs offering hope, especially for the obesity phenotype. (link.springer.com/article/10.100…). #HREV Josephine Harrington, MD Marc Bonaca MD MPH Andrew J Sauer MD orlyvardeny Mario Enrico Canonico

Finerenone in Heart Failure with Improved Ejection Fraction in #FINEARTSHF led by Maria A. Pabón, MD in JAMA Cardiology jamanetwork.com/journals/jamac…

ASCENT-03: SG superior to TPC chemo in 1L TNBC (PDL1- or IO ineligible) businesswire.com/news/home/2025…

It’s #ADCyear, and the good news keep coming! The ASCENT-03 phase 3 trial of SG vs chemo as 1L therapy for IO-ineligible mTNBC is announced to be positive, with significant PFS benefit. One more setting in which an ADC moves to first line. Exciting times! businesswire.com/news/home/2025…

Time to update the progress on #ADCyear in breast oncology. We already have 4 positive press releases. 2 (DB-09, ASCENT-04) will be presented at #ASCO25 (by Sara Tolaney!). Two more (DB-11, ASCENT-03) possibly at #ESMO25. 4 press releases to go to complete the list. Exciting times!

The good news: we’ll soon have more ADCs in earlier indications. The bad news: we have no biomarkers to guide their use. At Dana-Farber’s Breast Oncology Center we’re committed to fill this gap. At #ASCO25 we’ll present a pilot study with HER2DX & RPPA. Join us at the poster! meetings.asco.org/abstracts-pres…

For a patient with mTNBC treated with first line SG, most would give T-DXd in immediate sequence. Worth highlighting this Flatiron analysis we presented at #ASCO24 (now in press), finding worse outcomes with T-DXd for mTNBC if previously exposed to SG.

Viewpoint discusses how "skimming the median" can exaggerate survival gains in clinical trials, underscoring the need to critically evaluate Kaplan-Meier curves alongside hazard ratios. ja.ma/4jePW1F

🔴 Cardiac Amyloidosis in Older Adults With a Focus on Frailty: JACC: Advances Expert Consensus JACC Journals #Cardiology #CardioEd #Amyloidosis #FOAMed Abdulla A. Damluji, MD, PhD American College of Cardiology